← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2008Last known activity
Feb 28, 2025
Timeline
1910s
- Jun 1, 1918
The First People's Hospital of Changzhou— Founded
Drugs by trial phase (60 distinct, 43 trials)
Phase 4 (5 own, 0 via acquisition)
Phase 3 (18 own, 0 via acquisition)
Phase 2 (19 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Other trials (15 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Aneurysm
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Cholangiocarcinoma
- Colorectal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Glioma
- Hemorrhage
- Intracranial Aneurysm
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Nasopharyngeal Carcinoma
- Neoplasm Metastasis
- Ovarian Neoplasms
- Rectal Neoplasms
- Stomach Neoplasms
- Subarachnoid Hemorrhage
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
Recent trials (50)
- NCT06762782CollaboratorPhase 2Feb 28, 2025
- NCT06702657CollaboratorN/AFeb 15, 2025
- NCT06867991Lead sponsorPhase 3Nov 8, 2024
- NCT06554301CollaboratorPhase 1Sep 30, 2024
- NCT06456515Lead sponsorN/AJun 30, 2024
- NCT06394674CollaboratorPhase 2May 1, 2024
- NCT06216340Lead sponsorPhase 4Feb 15, 2024
- NCT06118034CollaboratorPhase 3Jan 1, 2024
- NCT06445257CollaboratorN/ASep 15, 2023
- NCT05934331Overall official - principal investigatorPhase 2Jul 27, 2023
- NCT05934331OfficialPhase 2Jul 27, 2023
- NCT05721651Lead sponsorPhase 2Apr 30, 2023
- NCT05721651Sponsor investigatorPhase 2Apr 30, 2023
- NCT05732662Lead sponsorPhase 2Apr 30, 2023
- NCT05732662Reponsible party - principal investigatorPhase 2Apr 30, 2023
Details
- Founded
- Changzhou, CN Jun 1, 1918
- Last known activity
- Feb 28, 2025